keyword
MENU ▼
Read by QxMD icon Read
search

1q21 multiple myeloma

keyword
https://www.readbyqxmd.com/read/28766538/-prognostic-value-of-1q21-amplification-in-multiple-myeloma
#1
T V Abramova, T N Obukhova, L P Mendeleeva, O S Pokrovskaya, E O Gribanova, V V Ryzhko, L A Grebenyuk, M V Nareyko, M V Solovyev, O M Votyakova, S M Kulikov, M A Rusinov, V G Savchenko
AIM: To determine the prevalence of amp1q21 and its relationship to the clinical manifestations of multiple myeloma (MM). SUBJECTS AND METHODS: In December 2009 to March 2016, a total 134 patients aged 30 to 81 years (median 57 years) underwent a pretreatment FISH-study of bone marrow (BM) with centromeric and locus-specific DNA probes to identify amp1q21, t(11;14), t(4;14), t(14;16), t(14;20), t(6;14), trisomies of chromosomes 5, 9, 15, del13q14, del17p13/TP53, and t(8q24)/cMYC...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28687565/ilf2-is-upregulated-by-1q21-amplification-in-multiple-myeloma
#2
(no author information available yet)
ILF2 induces resistance to DNA-damaging agents by enhancing splicing of DNA damage response mRNAs.
July 7, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28680482/combination-of-t-4-14-del-17p13-del-1p32-and-1q21-gain-fish-probes-identifies-clonal-heterogeneity-and-enhances-the-detection-of-adverse-cytogenetic-profiles-in-233-newly-diagnosed-multiple-myeloma
#3
Thomas Smol, Annika Dufour, Sabine Tricot, Mathieu Wemeau, Laure Stalnikiewicz, Franck Bernardi, Christine Terré, Benoît Ducourneau, Hervé Bisiau, Agnès Daudignon
BACKGROUND: Our aim was to set the FISH combination of del(17p13), t(4;14), 1q21 gain and del(1p32), four adverse cytogenetic factors rarely evaluated together, and compare our technical thresholds with those defined in the literature. METHODS: Two hundred thirty-three patients with MM at diagnosis were studied using FISH to target 4 unfavorable cytogenetic abnormalities: 17p13 deletion, t(4;14) translocation, 1p32 deletion and 1q21 gain. Technical thresholds were determined for each probe using isolated CD138-expressing PC from patients without MM...
2017: Molecular Cytogenetics
https://www.readbyqxmd.com/read/28669490/ilf2-is-a-regulator-of-rna-splicing-and-dna-damage-response-in-1q21-amplified-multiple-myeloma
#4
Matteo Marchesini, Yamini Ogoti, Elena Fiorini, Anil Aktas Samur, Luigi Nezi, Marianna D'Anca, Paola Storti, Mehmet Kemal Samur, Irene Ganan-Gomez, Maria Teresa Fulciniti, Nipun Mistry, Shan Jiang, Naran Bao, Valentina Marchica, Antonino Neri, Carlos Bueso-Ramos, Chang-Jiun Wu, Li Zhang, Han Liang, Xinxin Peng, Nicola Giuliani, Giulio Draetta, Karen Clise-Dwyer, Hagop Kantarjian, Nikhil Munshi, Robert Orlowski, Guillermo Garcia-Manero, Ronald A DePinho, Simona Colla
Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed multiple myeloma (MM) and is correlated with disease progression and drug resistance. Here, we provide evidence that the 1q21 amplification-driven overexpression of ILF2 in MM promotes tolerance of genomic instability and drives resistance to DNA-damaging agents. Mechanistically, elevated ILF2 expression exerts resistance to genotoxic agents by modulating YB-1 nuclear localization and interaction with the splicing factor U2AF65, which promotes mRNA processing and the stabilization of transcripts involved in homologous recombination in response to DNA damage...
July 10, 2017: Cancer Cell
https://www.readbyqxmd.com/read/28641640/-application-of-cd138-immunomagnetic-sorting-myeloma-cells-combined-with-fluorescence-in-situ-hybridization-for-detecting-cytogenetic-abnormalities-of-multiple-myeloma
#5
Lu Gao, Qing Liu, Yan Shi, Hui Dang, Qi He, Zheng Wang, Lin Feng, Ye Li, Xiao-Yan Wang, Na Li, Wen-Jie Song, Yan-Lin Wang, Shu Kong, Jin Lu, Xiao-Jun Huang, Yue-Yun Lai
OBJECTIVE: To investigate the efficiency of direct fluorescence in situ hybridization (D-FISH) versus FISH on CD138 immunomagnetic sorting myeloma cells (MACS-FISH) to detect the cytogenetic abnormalities of multiple myeloma. METHODS: Thirty-one patients with multiple myeloma (MM) were detected by D-FISH and MACS-FISH, using 5 probes, including 1q21, D13S319, RB1, IgH, P53. The IgH rearrangement positive patients were further examined by 3 IgH rearrangement subtype FISH probes including IgH/FGFR3, IgH/MAF and IgH/CCND1...
June 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28641639/-clinical-features-and-response-to-treatment-in-newly-diagnosed-multiple-myeloma-patients-with-deletion-17p
#6
Yan Liu, Xiao-Yan Ke, Jing Wang, Yan-Fang Wang, Fei Dong, Lei Tian, Wei Wan, Hong-Mei Jing
OBJECTIVE: To investigate the clinical features and response to therapies in multiple myeloma (MM) patients with del (17p). METHODS: A total of 122 newly diagnosed MM patients hospitalized in the Department of Hematology of Peking University Third Hospital between October 2012 and September 2016 were analyzed retrospectively. The fluorescent in situ hybridization(FISH) and G-binding staining were used for detection of cytogenetic abnormalities. These MM patients with del (17p) were divided into non-bortezomib chemotherapy (VAD or CHOP) group and bortezomib chemotherapy (PAD or PCD) group...
June 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28584253/prediction-of-outcome-in-newly-diagnosed-myeloma-a-meta-analysis-of-the-molecular-profiles-of-1-905-trial-patients
#7
V Shah, A L Sherborne, B A Walker, D C Johnson, E M Boyle, S Ellis, D B Begum, P Z Proszek, J R Jones, C Pawlyn, S Savola, M W Jenner, M T Drayson, R G Owen, R S Houlston, D A Cairns, W M Gregory, G Cook, F E Davies, G H Jackson, G J Morgan, M F Kaiser
Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036 patients from the NCRI Myeloma XI trial and linked these to overall survival (OS) and progression-free survival. Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard ratios (HRs) for OS of 1...
June 6, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28256461/observation-on-frequency-clinico-pathological-significance-of-various-cytogenetic-risk-groups-in-multiple-myeloma-an-experience-from-india
#8
Pratibha S Kadam Amare, Hemani Jain, Shraddha Nikalje, Manju Sengar, Hari Menon, Nitin Inamdar, P G Subramanian, Sumeet Gujral, Tanuja Shet, Sridhar Epari, Reena Nair
BACKGROUND & OBJECTIVES: Multiple myeloma (MM) is a plasma cell malignancy characterized by cytogenetic heterogeneity. In comparison with conventional karyotyping, fluorescence in situ hybridization (FISH) can efficiently detect various genetic changes in non-cycling plasma cells in 50-90 per cent of MM cases. The present study was undertaken in MM patients to evaluate the frequency and clinico-pathological significance of various cytogenetic abnormalities in the Indian population. METHODS: Interphase FISH was applied on purified plasma cells of 475 patients with MM using specific probes...
October 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28245391/-influence-of-chromosome-abnormality-on-therapeutic-efficacy-and-prognosis-of-newly-diagnosed-multiple-myeloma-treated-with-bortezomib
#9
Chao Sun, Jing Wang, Hong-Feng Guo, Xin Zhou, Yun-Feng Shen
OBJECTIVE: To explore the influence of chromosome abnormality on therapeutic efficacy and prognosis of patients with newly diagnosed multiple myeloma(MM) treated with bortezomib. METHODS: The clinical data of 152 patients with newly diagnosed MM were collected from January 2008 to December 2011. All patients received bortezo-mib-based chemotherapy and the therapeutic efficacy were investigated for 4 cycles later. The R banding and DNA probe were used to analyze the chromosome and gene (RB1 deletion, D13S319 deletion, P53 deletion, IgH rearrangement and 1q21 amplification) of chromosome specimens...
February 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28092996/chromosome-1-amplification-has-similar-prognostic-value-to-del-17p13-and-t-4-14-p16-q32-in-multiple-myeloma-patients-analysis-of-real-life-data-from-the-polish-myeloma-study-group
#10
Norbert Grzasko, Roman Hajek, Marek Hus, Sylwia Chocholska, Marta Morawska, Krzysztof Giannopoulos, Krzysztof Czarnocki, Agnieszka Druzd-Sitek, Barbara Pienkowska-Grela, Jolanta Rygier, Lidia Usnarska-Zubkiewicz, Dominik Dytfeld, Tadeusz Kubicki, Artur Jurczyszyn, Maciej Korpysz, Anna Dmoszynska
The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27694925/hyperhaploidy-is-a-novel-high-risk-cytogenetic-subgroup-in-multiple-myeloma
#11
J R Sawyer, E Tian, J D Shaughnessy, J Epstein, C M Swanson, C Stangeby, C L Hale, L Parr, M Lynn, G Sammartino, J L Lukacs, C Stein, C Bailey, M Zangari, F E Davies, F Van Rhee, B Barlogie, G J Morgan
Hyperhaploid clones (24-34 chromosomes) were identified in 33 patients with multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly, all hyperhaploid karyotypes were found to harbor monosomy 17p, the single most important risk stratification lesion in MM. A catastrophic loss of nearly a haploid set of chromosomes results in disomies of chromosomes 3, 5, 7, 9, 11, 15, 18, 19 and 21, the same basic set of odd-numbered chromosomes found in trisomy in hyperdiploid myeloma. All other autosomes are found in monosomy, resulting in additional clinically relevant monosomies of 1p, 6q, 13q and 16q...
November 4, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27662018/autotransplant-with-and-without-induction-chemotherapy-in-older-multiple-myeloma-patients-long-term-outcome-of-a-randomized-trial
#12
RANDOMIZED CONTROLLED TRIAL
Christian Straka, Peter Liebisch, Hans Salwender, Burkhard Hennemann, Bernd Metzner, Stefan Knop, Sigrid Adler-Reichel, Christian Gerecke, Hannes Wandt, Martin Bentz, Tim Hendrik Bruemmendorf, Marcus Hentrich, Michael Pfreundschuh, Hans-Heinrich Wolf, Orhan Sezer, Ralf Bargou, Wolfram Jung, Lorenz Trümper, Bernd Hertenstein, Else Heidemann, Helga Bernhard, Nicola Lang, Norbert Frickhofen, Holger Hebart, Ralf Schmidmaier, Andreas Sandermann, Tobias Dechow, Albrecht Reichle, Brigitte Schnabel, Kerstin Schäfer-Eckart, Christian Langer, Martin Gramatzki, Axel Hinke, Bertold Emmerich, Hermann Einsele
Autologous transplantation is controversial for older patients with multiple myeloma. The role of age-adjusted high-dose melphalan and the impact of induction chemotherapy cycles is still unclear. A total of 434 patients aged 60-70 years were randomly assigned to 4 cycles of standard anthracycline-based induction chemotherapy or no induction. For all patients, double autologous transplantation after melphalan 140 mg/m(2) (MEL140) was planned. The primary end point was progression-free survival. Of 420 eligible patients, 85% received a first transplant and 69% completed double transplantation...
November 2016: Haematologica
https://www.readbyqxmd.com/read/27638366/outcome-of-patients-with-multiple-myeloma-and-cks1b-gene-amplification-after-autologous-hematopoietic-stem-cell-transplantation
#13
Fabian Bock, Gary Lu, Samer A Srour, Sameh Gaballa, Heather Y Lin, Veerabhadran Baladandayuthapani, Medhavi Honhar, Maximilian Stich, Nina Das Shah, Qaiser Bashir, Krina Patel, Uday Popat, Chitra Hosing, Martin Korbling, Ruby Delgado, Gabriela Rondon, Jatin J Shah, Sheeba K Thomas, Elisabet E Manasanch, Berend Isermann, Robert Z Orlowski, Richard E Champlin, Muzaffar H Qazilbash
The gain/amplification of the CKS1B gene on chromosome 1q21 region is associated with a poor outcome in patients with multiple myeloma (MM). However, there are limited data on the outcome of patients with CKS1B amplification after a single high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HCT). We retrospectively evaluated the outcome of patients with CKS1B amplification who received an auto-HCT between June 2012 and July 2014 at our institution. We identified 58 patients with MM and CKS1B gene amplification detected by fluorescent in situ hybridization (FISH)...
December 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27592569/-genetic-abnormality-in-101-cases-of-plasma-cell-dyscrasias-by-fish-technology-and-cytogenetic-examination
#14
Pengfei Cao, Guiyuan Li, Qian Tan, Ying Zhang, Guoping Zhang, Xiaolin Li, Yuxiang He
OBJECTIVE: To investigate several abnormal genes by the fluorescence in situ hybridization (FISH) in multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and reactive plasmacytosis (RP), and to increase the diagnosis and differential diagnosis levels for these common plasma diseases. 
 METHODS: The clinical manifestations, image and laboratory tests and the FISH detection were retrospectively analyzed in 61 cases of newly diagnosed MM, 20 cases of MGUS and 20 cases of RP from August, 2012 to February, 2015 in the Xiangya Hospital of Central South University...
July 2016: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/27590108/allogeneic-hematopoietic-cell-transplantation-in-multiple-myeloma-focus-on-longitudinal-assessment-of-donor-chimerism-extramedullary-disease-and-high-risk-cytogenetic-features
#15
Leo Rasche, Christoph Röllig, Gernot Stuhler, Sophia Danhof, Stephan Mielke, Goetz Ulrich Grigoleit, Lea Dissen, Lea Schemmel, Jan Moritz Middeke, Viktoria Rücker, Martin Schreder, Johannes Schetelig, Martin Bornhäuser, Hermann Einsele, Christian Thiede, Stefan Knop
Although generally not applied as first-line treatment of multiple myeloma, allogeneic hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation approach in high-risk patients, preferentially within the framework of clinical trials. In this study, we investigated whether decreasing donor chimerism (DC) is predictive for relapse. In addition, we comprehensively determined the impact of several other disease- and treatment-related factors on outcome. One hundred fifty-five multiple myeloma patients whose DC status was followed serially by the short tandem repeat-based techniques at a single lab were included in this retrospective study...
November 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27531777/-expression-of-cd56-and-cd19-in-patients-with-newly-diagnosed-multiple-myeloma-and-their-relationship-with-karyotypes-and-prognosis
#16
Quan Qiu, Ping Zhu, Mang-Ju Wang, Xu-Zhen Lu, Yu-Jun Dong, Yu-Hua Sun, Li-Hong Wang, Ying Zhang, Ding-Fang Bu, Wen-Sheng Wang, Ze-Yin Liang, Wei Liu, Zhi-Xiang Qiu, Jin-Ping Ou, Xi-Nan Cen
OBJECTIVE: To study the relationship between surface markers of CD56 and CD19 and karyotypes and prognosis in multiple myeloma. METHODS: A total of 126 cases of newly diagnosed multiple myeloma in the first hospital of Peking university from 2011 to 2015 were enrolled in this study. Cytogenetic abnormalities and immunophenotypes were detected by using fluorescence in situ hybridization and flow cytometry respectively before chemotherapy. Bone marrow smear was used for detection of abnormal plasma cell infiltration...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27257181/prognostic-impact-of-cytogenetic-aberrations-in-al-amyloidosis-patients-after-high-dose-melphalan-a-long-term-follow-up-study
#17
Tilmann Bochtler, Ute Hegenbart, Christina Kunz, Axel Benner, Christoph Kimmich, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Martin Granzow, Peter Dreger, Anthony D Ho, Anna Jauch, Stefan O Schönland
Cytogenetic aberrations detected by interphase fluorescence in situ hybridization (iFISH) of plasma cells are routinely evaluated as prognostic markers in multiple myeloma. This long-term follow-up study aimed to assess the prognosis of systemic light chain amyloidosis (AL) patients treated with high-dose melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH results. Therefore, we analyzed a consecutive cohort of 123 AL patients recruited from 2003 to 2014. HDM was safe, with only 1 of 123 patients dying as a result of treatment-related mortality, and effective, with a complete remission (CR) rate of 34%...
July 28, 2016: Blood
https://www.readbyqxmd.com/read/27175647/prognostic-impact-of-cytogenetic-abnormalities-in-multiple-myeloma-a-retrospective-analysis-of-229-patients
#18
Yuan Jian, Xiaolei Chen, Huixing Zhou, Wanqiu Zhu, Nian Liu, Chuanying Geng, Wenming Chen
The identification of specific cytogenetic abnormalities by interphase fluorescence in situ hybridization (i-FISH) has become a routine procedure for prognostic stratification of multiple myeloma (MM) patients. In this study, the prognostic significance of cytogenetic abnormalities detected by interphase fluorescence in situ hybridization (iFISH) in 229 newly diagnosed multiple myeloma patients was retrospectively analyzed. Results showed that del (17p), t(4;14), and 1q21 gain were adverse predictors of progression-free survival (PFS)...
May 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27129167/potential-role-of-exosome-associated-microrna-panels-and-in-vivo-environment-to-predict-drug-resistance-for-patients-with-multiple-myeloma
#19
Li Zhang, Ling Pan, Bing Xiang, Huanling Zhu, Yu Wu, Meng Chen, Pujun Guan, Xingli Zou, C Alexander Valencia, Biao Dong, Jianjun Li, Liping Xie, Hongbing Ma, Fangfang Wang, Tian Dong, Xiao Shuai, Ting Niu, Ting Liu
Multiple myeloma (MM) is the second most common hematologic neoplasms and an appropriate in vivo environment for myeloma cells has potential implications for initiation, progression, and metastasis of MM. Exosomes, entities carrying microRNAs (miRNAs) to target locations, participate in the cross-talk between myeloma cells and nonmalignant components of the in vivo environment. This study disclosed the emerging roles of circulating exosome-associated miRNAs in drug resistance (DR) of MM. To this end, the medical records of consecutively hospitalized MM patients, who received novel agents-based therapies, were analyzed...
May 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27101987/cytogenetics-and-survival-of-multiple-myeloma-isolated-and-combined-effects
#20
Theodoros N Sergentanis, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Theodora Psaltopoulou
BACKGROUND: A variety of clinical and laboratory prognostic factors for multiple myeloma (MM) have been addressed in published studies. The prognostic significance of cytogenetic abnormalities is also under investigation. PATIENTS AND METHODS: The present study evaluated the potential prognostic role of cytogenetic events and their combinations in terms of overall survival in a large cohort of unselected patients with MM (n = 432). Multivariate Cox regression analysis was performed, adjusting for age, gender, Chronic Kidney Disease Epidemiology Collaboration Kidney Disease: Improving Global Outcomes classification, International Staging System score, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase, serum calcium, platelet count, and blood hemoglobin...
June 2016: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
98739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"